Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D00CGX
|
|||
Former ID |
DNCL001701
|
|||
Drug Name |
DV-1179
|
|||
Indication | Autoimmune disease [ICD-11: 4A40-4A45; ICD-9: 279] | Phase 1 | [1] | |
Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Discontinued in Phase 1 | [2] | ||
Company |
Dynavax Technologies
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Toll-like receptor 7 (TLR7) | Target Info | Modulator | [3] |
Toll-like receptor 9 (TLR9) | Target Info | Modulator | [3] | |
KEGG Pathway | Toll-like receptor signaling pathway | |||
Chagas disease (American trypanosomiasis) | ||||
African trypanosomiasis | ||||
Malaria | ||||
Tuberculosis | ||||
Measles | ||||
Herpes simplex infection | ||||
Influenza A | ||||
NetPath Pathway | BCR Signaling Pathway | |||
TCR Signaling Pathway | ||||
Panther Pathway | Toll receptor signaling pathway | |||
Reactome | PI3K Cascade | |||
Trafficking and processing of endosomal TLR | ||||
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | ||||
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | ||||
MyD88 dependent cascade initiated on endosome | ||||
WikiPathways | Toll-like receptor signaling pathway | |||
Toll-Like Receptors Cascades | ||||
MyD88 dependent cascade initiated on endosome | ||||
Trafficking and processing of endosomal TLR | ||||
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | ||||
Regulation of toll-like receptor signaling pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035150) | |||
REF 3 | Company report (Dynavax) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.